meeting of the New England Ophthalmological Society...Staff have been furloughed. Practices are under severe financial strain and stress. And yet, there are so many good things too

779thmeeting of the

New England Ophthalmological Society

NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPSwith The Stephen Foster Lecture on Ocular Inflammation

RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGESwith The Joan W. Miller, MD Lecture

April 24, 2020Virtual meeting available atWWW.NEOS-EYES.ORG

New England Ophthalmological Society PO Box 549127, Waltham, MA 02454-9127 | tel: 781-434-7656

email: [email protected] | www.neos-eyes.org

NEOS is now on Twitter and Instagram Follow us @NEOS_Eyes

AMA Credit Designation StatementThe New England Ophthalmological Society designates this enduring material for a

maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation require-ments and policies of the Accreditation Council for continuing Medical Education. The New

England Ophthalmological Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.

the 779th meeting of

The New England Ophthalmological Society, Inc.A Public Foundation for Education in Ophthalmology

VIRTUAL MEETING AVAILABLE ATWWW.NEOS-EYES.ORGApril 24, 2020

NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPSWITH THE STEPHEN FOSTER LECTURE ON OCULAR INFLAMMATION

Lucia Sobrin, MD, MPH, Moderator and Program Committee Coordinator

RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGESWITH JOAN W. MILLER, MD LECTURE

Peter Chang, MD, Moderator Brian Kim, MD, Program Committee Coordinator

The 779th Meeting ofThe New England Ophthalmological Society, Inc.

A Public Foundation for Education in Ophthalmology

Virtual meeting available at WWW.NEOS-EYES.ORG

April 24, 2020

NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPSLucia Sobrin, MD, MPH, Moderator and Program Committee Coordinator

-------------------------------------------------------

RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGESPeter Chang, MD, Moderator

Brian Kim, MD, Program Committee Coordinator

-------------------------------------------------------

AMA Credit Designation Statement The New England Ophthalmological Society designates this enduring material for a

maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation StatementThis activity has been planned and implemented in accordance with the

accreditation requirements and policies of the Accreditation Council for continuing Medical Education. The New England Ophthalmological Society is accredited by the Massachusetts Medical Society to provide continuing medical education for

physicians.

New England Ophthalmological SocietyPO Box 549127, Waltham, MA 02454-9127

www.neos-eyes.org | [email protected] | T:781-434-7656

@NEOS_Eyes

2 | New England Ophthalmological Society

Nabeel Jarudi, MDApril 2nd, 2020

In Memoriam:

778th Meeting | 3

MESSAGE FROM THE PRESIDENT

MARY K. DALY, MD

Dear NEOS Membership,

In my very first letter to the membership in the September 2019 program booklet, I wrote “This academic year will bring us into the year 2020. That is a special year for us...”

None of us imagined this kind of ‘special.’

Words like ‘fluid,’ ‘uncharted,’ ‘unprecedented’ are said, heard, and read multiple times a day.

The fear surrounding the virus’s success at causing illness and death is compounded by the deep anxiety and dread surrounding its incredible impact on the economy and life as we know it.

On March 9th, the NEOS Board announced the first cancellation of a NEOS meeting in the Society’s living history. Our members have deferred all non-urgent, routine appointments and surgeries. Staff have been furloughed. Practices are under severe financial strain and stress.

And yet, there are so many good things too. Maybe not ones we imagined, but still good. Telephone and virtual visits are being rapidly integrated into practices to ensure patients continue to have access to care. That integration began before anyone knew if or how reimbursement for these new types of visits would be possible. As always, our members are putting their patients at the forefront of what they do. Video-conferencing platforms, though perhaps clumsy at first, are now offering easy and high-quality access to educational programs at our hospitals, practices, academic programs and Veterans Affairs medical centers. Attendance at some of these meetings has been record breaking, all without the commute or fighting for a parking space.

Colleagues have volunteered to assist their hospitals with much needed non-ophthalmic medical care, ‘rolling up their sleeves’ and jumping in to serve and combat this incredible crisis on the front lines, in incident command centers, and wherever they can offer assistance. Towns have come together to sew cloth masks with HEPA filters to try and fight community spread. By distributing these homemade masks to private citizens for free, these town efforts are at the same time helping to preserve precious medical grade PPE for hospital staff and first responders. Restaurants, despite their desperate financial situation, are donating hot meals to the medical and surgical units across Boston. Many of us have been able to connect with our patients by phone in a way that is not always possible in the fast-paced clinic. The patients are so grateful to receive a call from their doctor. It is so rewarding to have the ability to offer them some caring words, and in many instances, much needed human contact in this new world of social distancing.


This strange time is forcing uncomfortable changes, but some of that change will be for the better.

One big change for NEOS will be our first ever virtual meeting. This will be available online starting April 24, 2020. Many, many thanks go out to the moderators, guests-of-honor, the speakers, the Program and IT committees, and our executive assistant, Miguel Ocque, for their diligence and innovation in putting this novel format together so that NEOS can continue to achieve its educational mission in these unique circumstances. We are pleased to have Steve Charles, MD, FACS, FICS, present the Joan W. Miller, MD Lecture, and Quan Nguyen, MD, MSc, to deliver the inaugural Stephen Foster Lecture on Ocular Inflammation. Our exhibitors are so important to us, and there will be a Supporter Page on the NEOS website for the April 24th, 2020, meeting. Please be sure to visit the site (bring your own coffee and snacks!).

In this 136th year of NEOS, the Board and committees continue tirelessly to ensure your educational and professional needs are fulfilled. We hope you enjoy the 779th meeting of the New England Ophthalmological Society in virtual format for the first time in our history!

Stay well and safe,Mary K. Daly, MDPresident of NEOS

778th Meeting | 5

QUAN DONG NGUYEN, MD, MSc

Born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980, Dr. Quan Dong Nguyen currently is Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.

After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center.

Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema.

Dr. Nguyen has led the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.

Throughout his career thus far, Dr. Nguyen has been prolific to share his scientific work through numerous manuscripts published in the literature. He serves on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging – Retina, among others. Given his scientific achievements and accomplishments, Dr. Nguyen has been chosen as the Inaugural Editor-in-Chief of American Journal of Ophthalmology Case Reports, which has been launched in the fall of 2015 as the companion journal to the American Journal of Ophthalmology.

GUEST OF HONOR AND STEPHEN FOSTER LECTURE ON OCULAR INFLAMMATION LECTURER


At the Byers Eye Institute at Stanford, Dr. Nguyen has an active uveitis and ocular inflammatory diseases as well as clinical and surgical retina practice while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and clinical and research retina and uveitis fellows at Stanford.

Dr. Nguyen is married to Dr. Diana V. Do, who is also Professor of Ophthalmology at Stanford. They have three beautiful daughters: Alexandra, Olivia, and Madelyne, and live in Silicon Valley.

778th Meeting | 7

THE STEPHEN FOSTER LECTURE ON OCULAR INFLAMMATION

C. Stephen Foster, MD was born and raised in West Virginia, received his Bachelor of Science Degree in Chemistry at Duke University, with Distinction and Phi Beta Kappa in 1965, and received his Doctor of Medicine Degree at Duke University Medical Center, in 1969, being elected to Alpha Omega Alpha. He trained in Internal Medicine at Duke University Hospital from 1969-1970, and at the National Heart and Lung Institute, at the National Institutes of Health in Bethesda,

Maryland, from 1970 to 1972, during which time he also taught Internal Medicine, with an appointment as Instructor in Medicine at the George Washington University Hospital in Washington, DC. In 1972, Dr. Foster entered his Ophthalmology Residency training program at Washington University (Barnes Hospital), in St. Louis, Missouri, and having completed that in 1975, traveled to Boston to do two additional Fellowship trainings in Cornea and External Diseases, and in Ocular Immunology. He completed this training in 1977 and was invited to join the full-time faculty of the Department of Ophthalmology of Harvard Medical School, where he was a member of the Cornea Service and Director of the Residency Training Program at the Massachusetts Eye and Ear Infirmary. He began his independent research in 1977 and has since been continuously funded by grants from the National Institutes of Health.

After 30 years on the full-time faculty of Massachusetts Eye and Ear Infirmary, he established his own private practice – The Massachusetts Eye Research and Surgery Institution, a state-of-the-art practice with its own chemotherapy infusion suite and phlebotomy lab. Dr. Foster continues to direct a research laboratory at the Massachusetts Eye Research and Surgery Institution (MERSI), through the support of his newly created research foundation, the Ocular Immunology and Uveitis Foundation, and continues his teaching activities and training fellows as a Clinical Professor of Ophthalmology at Harvard Medical School. He has also authored 1,000 published papers and 14 textbooks.


STEVE CHARLES, MD

Steve Charles, MD has developed many of the techniques and devices used by vitreoretinal surgeons worldwide. He has performed over 38,000 vitreoretinal surgeries, lectured in 51 countries and operated in 25, delivered 18 named lectures, and well over 1000 speaking trips. He authored a leading textbook in the field which is now in the 5th edition and in 6 languages

and authored over 174 articles in the medical literature and over 50 book chapters. He is a Fellow in the American College of Surgeons and International College of Surgeons and a member of the Retina Society, Macular Society, American Society of Retinal Specialists, Club Jules Gonin, American Society of Cataract and Refractive Surgery, American Academy of Ophthalmology, and the Dowling Society. He served on the Board of Governors of the ARVO Foundation for Eye Research He is on the editorial board of Retina and a reviewer for Ophthalmology, Archives of Ophthalmology, American Journal of Ophthalmology, and British Journal of Ophthalmology. He has received the Laurate honor from the AAO, gave the Schepens lecture at the Retina Society and the Kelman lecture at the ASCRS, received the Wacker Medal from the Club Jules Gonin, the first Founders Medal from the Vitreous Society, was inducted into the University of Miami School of Medicine Medical Alumni Association Hall of Fame, and was named by Ocular Surgery News as one of the top ten innovators in the past 25 years. He is consistently listed in Best Doctors in America and Becker’s Top 34 Ophthalmologists in America. He is a Clinical Professor of Ophthalmology at the University of Tennessee.

After four years in engineering school, he completed medical school at the University of Miami Leonard Miller School of Medicine. He did research all four medical school years at the Bascom Palmer Eye Institute. After a medical internship at Jackson Memorial Hospital in Miami he completed a residency at the Bascom Palmer Eye Institute followed by a two year Clinical Associate appointment at the National Eye Institute (NIH); focused on vitreoretinal surgery, angiogenesis research, and medical device engineering.

He is a mechanical and electrical engineer and has well over 100 issued or pending patents. He is a consultant for Alcon Laboratories and the principal architect of the Alcon Accurus and Alcon Constellation Vision System.

He is the Founder of MicroDexterity Systems, which developed robots for dexterity enhancement for minimally invasive knee and hip replacement, spine surgery, and skull base neurosurgery. Stryker, Inc. acquired MicroDexterity Systems, in December 2009. He is a cofounder, systems engineer, and Chairman of CamPlex Inc, developing advanced visualization technology for MIS spine, neurosurgery and trans-oral approaches to head

GUEST OF HONOR AND JOAN W. MILLER, MD, LECTURER

778th Meeting | 9

and neck cancer. Dr Charles in on the Scientific Advisory Board of Opsis, developing stem cell derived outer retinal replacement. Dr Charles was inducted into the Society of Entrepreneurs; a Memphis based organization.

Steve Charles is an Airline Transport Pilot, Multi-Engine, Instrument rated pilot with Type Ratings in Citation 500, 560, 650, Falcon 50and Sabre 65 jets and currently owns and flies a Sabre 65.

Dr Charles has three daughters and four grandchildren. The oldest daughter is a gyn surgeon, the middle daughter is a family physician and the youngest is a team building/ropes course/climbing wall/zipline expert.


Joan W. Miller, MD, FARVO, is Henry Willard Williams Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School (HMS). She also serves as Chief of Ophthalmology at both). A Massachusetts Eye and Ear and Massachusetts General Hospital (MGH graduate of Massachusetts Institute of Technology, Dr. Miller received her MD and ophthalmology residency training at HMS. She completed a clinical and research fellowship in vitreoretinal

disease at Mass. Eye and Ear. An internationally recognized expert on retinal disorders, Dr. Miller is credited with co-developing photodynamic therapy (PDT) with verteporfin (Visudyne®), the first pharmacologic treatment for age-related macular degeneration (AMD). She also co-discovered the role of vascular endothelial growth factor (VEGF) in eye disease, and demonstrated the therapeutic potential of VEGF inhibitors, forming the scientific basis of anti-VEGF therapy for neovascular AMD, diabetic retinopathy, and related conditions.

Ongoing investigations include the genetics and metabolomics of AMD, strategies for early intervention in AMD, and neuroprotective therapies for retinal disease. Her clinical and scientific innovations have resulted in 11 U.S. patents and 10 international patents to date. Dr. Miller is the first female physician to achieve the rank of Professor of Ophthalmology at HMS, the first woman to chair the HMS Department of Ophthalmology, and the first woman to serve as Chief of Ophthalmology at Mass. Eye and Ear and MGH. Her scholarly contributions include more than more than 150 original research articles, 20 clinical trial reports (as a member of the investigative team), 40 reviews, and 30 book chapters. Dr. Miller is an editor of the journal Ophthalmology and several textbooks, including the 3rd edition of Albert and Jakobiec’s Principles and Practice of Ophthalmology (Saunders), Retinal Disorders: Genetic Approaches to Diagnosis and Treatment (Cold Spring Harbor Laboratory Press), and Endophthalmitis (Springer, forthcoming). Among Dr. Miller’s numerous honors, she is a laureate of the 2014 António Champalimaud Vision Award, the highest distinction in ophthalmology and visual science. In 2015, Dr. Miller became the first woman to receive the Mildred Weisenfeld Award for Excellence in Ophthalmology from the Association for Research in Vision and Ophthalmology (ARVO), and was inducted into the prestigious National Academy of Medicine (formerly the Institute of Medicine).

Since 2006, Dr. Miller has served in several leadership capacities for the New England Ophthalmological Society, including: Program Committee member, Admissions Committee member, Vice President, and President (2013-2014).

Previous Miller Lecturers

2016 – David Brown, MD, FACS2018 – Peter K. Kaiser, MD

JOAN W. MILLER, MD, LECTURE

778th Meeting | 11

SESSION 1

NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPSLucia Sobrin, MD, MPH, Moderator and Program Committee Coordinator

Professional Practice Gaps: Feedback from NEOS members and Program committee review identified that practice gaps included lack of familiarity with the rapidly expanding treatment options for glaucoma and dry eyes and lack of knowledge about the novel biologic agents available for the treatment of non-infectious uveitis.

Program Objectives: The content and format of this educational activity has been specifically designed to fill the practice gaps in the audience’s current potential scope of professional activities by:

1. To become familiar with the new agents available for treatment of glaucoma and dry eyes.

2. To understand the differences between previously available and newly available anti-VEGF agents for the treatment of retina and choroidal vascular disease

3. To become familiar with new agents that are currently available for the treatment of non-infectious uveitis.

Introduction of Program ...................................Moderator: Lucia Sobrin, MD, MPH Topical Antibiotic Prophylaxis in Post-Surgical Endophthalmitis ....................................................................................................Shiyoung Roh, MD Dropless Cataract Surgery .............................................................Z. Katie Luo, MD The Landscape of Glaucoma Drops .............................................Husam Ansari, MD Introduction of Guest of Honor ......................................... Lucia Sobrin, MD, MPH Regression of Diabetic Retinopathy with Anti-VEGF Treatment: Meta-analysis of 4 Pivotal Clinical Trials ..................Quan Dong Nguyen, MD, MSc Innovations in Dry Eye and Ocular Allergy Therapeutics ...............Erin S. Fogel, MD Drug Delivery in Ophthalmology .............................................. Joseph Ciolino, MD Introduction of Inaugural Stephen Foster Lecture on Ocular Inflammation ................ Lucia Sobrin, MD, MPH The Stephen Foster Lecture on Ocular Inflammation: Pharmacotherapy in Development for Non-infectious Posterior Uveitis: What Can We Expect from Clinical Trials? .................................................................................Quan Dong Nguyen, MD, MSc


RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGESPeter Y. Chang, MD, Moderator

Brian T. Kim, MD, Program Committee Coordinator

Professional Practice Gaps: Retinal detachment has not been a theme in NEOS in over 5 years, and audience has been seeking an overview of various types of retinal detachment and their management.

Program Objectives: The content and format of this educational activity has been specifically designed to fill the practice gaps in the audience’s current potential scope of professional activities by:

1. Demonstrating the surgical principles in adult and pediatric retinaldetachment repair

2. Discussing the challenges Vitreoretinal surgeons face in diabetic tractionalretinal detachment and proliferative vitreoretinopathy (PVR)-associatedrecurrent retinal detachment

3. Familiarizing the audience with special techniques utilized by Vitreoretinalsurgeons in difficult retinal detachment repairs

Introduction of Program .......................................... Moderator: Peter Y. Chang, MDVitrectomy for Rhegmatogenous Retinal Detachment .............. Richard Watson, MDScleral Buckling and the Lost Art of Retinal Drawing ...................Robert Millay, MDPneumatic Retinopexy: Indications,Techniques, and Outcomes ....................................................... Anthony Joseph, MDManagement of Proliferative Vitreoretinopathy: Where Are We Today and Where Are We Going? ........................David R. Lally, MDIntroduction of Guest of Honor .................................................Peter Y. Chang, MD The Joan W. Miller, MD Lecture:Medium Term PFO for Inferior RD, Giant Breaks andMacular Patch Graft ................................................Steve Charles, MD, FACS, FICSSpecial Considerations in Pediatric Retinal Detachment ..........Caroline Baumal, MDFailure Modes in Retinal Detachment Surgery .........Steve Charles, MD, FACS, FICSAdventures in Tractional Retinal Detachment Repair ............................................................................... Kristen Nwanyanwu, MD, MBA

SESSION 2

778th Meeting | 13

TOPICAL ANTIBIOTIC PROPHYLAXIS IN POST-SURGICAL ENDOPHTHALMITISShiyoung Roh, MD

LAHEY HOSPITAL AND MEDICAL CENTER, PEABODY, MA

Objective: Review studies and better understand role of prophylactic topical antibiotics

Endophthalmitis is an uncommon but potentially devastating complication of cataract surgery, with the primary source of infection being the patient’s own flora.¬¬ Reported rates of postoperative endophthalmitis from cataract surgery range from 0.04%-0.29%. In order to decrease the risk of endophthalmitis, prophylactic measures are taken. The use of Povidone-iodine has been shown to be one of the most effective prophylactic treatments in the prevention of post-cataract endophthalmitis. In addition, topical antibiotics are used perioperatively for prophylaxis against infection. Topical fluoroquinolones have been widely used as prophylaxis in cataract surgery, with fourth generation fluoroquinolones showing a significantly decreased incidence of endophthalmitis compared to prior generations. Several studies have also shown a decreased incidence of endophthalmitis with the use of prophylactic intracameral antibiotics for phacoemulsification. However, in the era of developing antibiotic resistance, there is growing concern of overutilization of newer broad-spectrum antibiotics, especially for prophylaxis. With the use of intracameral antibiotics, there are potential issues with sterility, errors in dilution, or the inadvertent use of preserved formulations leading to Toxic Anterior Segment Syndrome (TASS). Additionally, many of these newer antibiotics are costly, and it is important to evaluate whether the higher costs associated with these antibiotics contribute to quality of care.

References: Packer M, Chang DF, Dewey SH, Little BC, Mamlis N, Oetting TA, Talley-Rostov A, Yoo SH, ASCRS Cataract Clinical Committee. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg 2011;37:1699-1714 Speaker, Mark G., and Jerry A. Menikoff. Prophylaxis of Endophthalmitis with Topical Povidone-iodine. Ophthalmology 1991;98: 1769-1775 Roh S., Weiter W., Presti K., Duncan, R., Ramsey D.J. Topical Antibiotic Prophylaxis on the Incidence of Endophthalmitis Following Phacoemulsification Surgery: A Comparison of Gatifloxacin Versus Polymyxin B-Trimethoprim. Archives of Ophthalmology & Optometry. 2019; 2(1): 08-18 Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600,000 surgeries. Ophthalmology 2017 Jun;124(6):768-775 Holland EJ, McDonald MB, Parekh JG, Sheppard JD. Antibiotic resistance in acute postoperative endophthalmitis. Ophthalmology 2014;121:S1-S9


DROPLESS CATARACT SURGERYZ. Katie Luo, MD

MASSACHUSETTS EYE AND EAR INFIRMARY, LONGWOOD, MA

Objective: To understand the current development in intra-operative and post-operative drug delivery strategies aiming at drop-free cataract surgery

There are 20 million cataract surgeries being done annually worldwide. Despite the high success rate of the procedure itself, poor adherence to the post-operative treatment regimen hinders many from timely recovery and increases the risk of vision-threatening complications. This presentation summaries current development in various intra-operative and post-operative drug delivery strategies, all of which aim at the removal of patient compliance from the equation, therefore optimize and standardize the healing process.

References: 1. Shah TJ, Conway MD and Peyman GA. Intracameral dexamethason injection in the treatment of catract surgery induced inflammation:design, development, and place in therapy. Clin Ophthalmol 2018; 12:2223-2235 2. Shorstein NH and Myers WG. Drop-free approaches in cataract surgery. Curr Opin Ophthalmol 2020;31:67-73 3. Haripriya A, Chang DF and Ravindran RD. Endopthalmitis reduction with intracameral modifloxacin in eyes with and without surgical complications: results from 2 million consecutive cataract surgeries. J Cataract Refract Surg 2019;45:1226-1233

778th Meeting | 15

LANDSCAPE OF GLAUCOMA DROPSHusam Ansari, MD

OPHTHALMIC CONSULTANTS OF BOSTON, BOSTON, MA

Objective: To provide a comprehensive review of commonly-used topical glaucoma med-ications.

Topical medications remain the mainstay of current glaucoma management, being utilized as first-line therapy for most patients. This presentation will review all of the commonly-used topical glaucoma medications. Each medication will be reviewed in terms of indications, mechanisms of actions, effectiveness, side effects, and accessibility within the health care system. Special emphasis will be paid to the newest topical medications that have come to market in the past 2 years: latanoprostene bunod, netarsudil mesylate, and the combination agent latanoprost/netarsudl.

References: 1. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973. 2. Medeiros FA, Martin KR, Peace J, Sforzolini BS, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259. 3. Serle JB, Katz LJ, McLaurin E, ROCKET-1 and ROCKET-2 Study Groups, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127.


REGRESSION OF DIABETIC RETINOPATHY WITH ANTI-VEGF TREATMENT: META-ANALYSIS OF 4 PIVOTAL CLINICAL TRIALS

Quan Dong Nguyen, MD, MSc

BYERS EYE INSTITUTE AT STANFORD UNIVERSITY, STANFORD, CA

Objective: To illustrate that treatment of earlier stages of DR with intravitreal VEGF in-hibitors may help to prevent development of vision threatening proliferative diabetic ret-inopathy

Diabetic retinopathy is the leading cause of vision loss in working-age adults. Meta-analysis of 4 similar randomized clinical trials involving RBZ in eyes with DR and DME (patients with prior-PRP were excluded) – RIDE and RISE, DRCR.net Protocols I and T – was performed to determine the most optimal window of maximum efficacy for treating diabetic retinopathy.

References: N/A

778th Meeting | 17

INNOVATIONS IN DRY EYE AND OCULAR ALLERGY THERAPEUTICSErin S. Fogel, MD

CONCORD EYE CENTER, CONCORD, NH

Objective: To update attendees on newer therapeutic approaches to dry eye and ocular allergy

Dry eye is prevalent in our modern society with estimates that it affects 16 million people in this country. What is more, our patients are seeking help as they spend their day in climate controlled work places, staring at screens, all of which takes its toll on comfort and vision. Advances in research, like the TFOS DEWS II report, have broadened our understanding of the complex nature of dry eye to include the role of inflammation, the loss of tear film homeostasis, neurosensory abnormalities, and the importance of the meibomian glands and eyelids. This talk will cover newer therapeutic agents, both drops and devices, that address dry eye as well as where they fit in to this new paradigm. Some of these drops are new molecules, others are familiar to us, like cyclosporin, but come with innovations in delivery systems that promise improved penetration, efficacy, and lower side effect profiles. Evaporative dry eye, meibomian gland disease, and blepharitis are getting center stage attention with the development and expansion of devices to treat the eyelids. Less innovation is happening in ocular allergy treatment, but this talk will cover our current therapeutics and an update on newer agents.

References: 1.Farrand KF, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmology. 2017;182:90-98. 2.TFOS International Dry Eye Workshop (DEWS II). Ocular Surf. 2017;15:276-283 3.Mandel A, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporin for dry eye disease. Pharm Res. 2019;36;36.


DRUG DELIVERY IN OPHTHALMOLOGYJoseph Ciolino, MD

MEEI, BOSTON, MA

Objective: To present the potential advantages, challenges, and clinical options for sustained drug delivery to the eye.

Most drugs have been traditionally delivered to the front of the eye by ophthalmic solutions or ointments. Because a means of sustained drug delivery to the eye may improve patient adherence and can possibly be more effective than drops and ointments, there has been an increased interest in developing sustained drug delivery to the eye. Many approaches have been described, but there are some unique challenges associated with ophthalmic drug delivery that may limit their effectiveness and patient acceptance. Collagen shields and pilocarpine-containing, polymermembrane unit (Ocusert) were two of the first products available for sustained ocular drug delivery. Decades later, three new products have been FDA-approved for sustained drug delivery to the front of the eye over the last several years. We will review the use of the FDA-approved products.

References: N/A

778th Meeting | 19

PHARMACOTHERAPY IN DEVELOPMENT FOR NON-INFECTIOUS POSTERIORUVEITIS: WHAT CAN WE EXPECT FROM CLINICAL TRIALS?

Quan Dong Nguyen, MD, MSc

BYERS EYE INSTITUTE AT STANFORD UNIVERSITY, STANFORD, CA

Objective: To recognize different pathways to regulate inflammation in the management of uveitis

Uveitis is a spectrum of inflammatory disorders characterised by ocular inflammation and is one of the leading causes of preventable visual loss. The main aim of the treatment of uveitis is to control the inflammation, prevent recurrences of the disease, and preserve vision, while minimizing the adverse effects associated with the therapeutic agents. Initial management of uveitis relies heavily on the use of corticosteroids. However, monotherapy with hi-dose corticosteroids is associated with side effects and cannot be maintained long term. Therefore, steroid-sparing agents are needed to decrease the burden of steroid therapy. Currently, the therapeutic approach for non-infectious uveitis (NIU) consists of a stepladder strategy with the first line option being corticosteroids in various formulations followed by the use of first, second, and third line agents in cases with suboptimal steroid response. Unfortunately, the agents currently at our disposal have limitations such as having a narrow therapeutic window along with their own individual potential side-effect profiles. Therefore, research has been targeted to identify newer drugs as well as new uses for older drugs that target specific pathways in the inflammatory response. Such efforts are made in order to provide a targeted and safer therapy with reduced side effects and greater efficacy. Several specially designed molecular antibodies are currently in various phases of investigations that can potentially halt the inflammation in patients with NIU. In this presentation, we will provide a comprehensive overview of the current and upcoming therapeutic options for patients with NIU.

References: N/A


VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENTRichard Watson, MD

MASS EYE AND EAR, PLAINVILLE, MA

Objective: Explain the fundamentals of vitrectomy surgery for rhegmatogenous retinal detachment.

Vitrectomy surgery is the most common treatment for rhegmatogenous retinal detachment. This lecture will discuss the diagnosis of retinal detachment and the steps to take after diagnosis including the timing of intervention and how to prepare a patient for vitrectomy surgery. The steps of vitrectomy surgery will be discussed along with video demonstration. This talk is directed to all ophthalmologists and is a good review for vitreoretinal surgeons.

References: 1. Charles S, Calzada J, Wood B. Vitreous Microsurgery. LWW. September 2010. 2. Schachat A, et al. Ryan’s Retina. Elsevier. May 2017. 3. Noemi L, Wong D. Complication of Vitreo-retinal Surgery. LWW. May 2013.

778th Meeting | 21

SCLERAL BUCKLING AND THE LOST ART OF RETINAL DRAWINGRobert Millay, MD

UNIVERSITY OF VERMONT, DEPT OF SURGERY/OPHTHALMOLOGY, BURLINGTON, VT

Objectives: 1) Understand the importance AND TIMING of scleral depression in the evaluation of acute flashes and floaters consistent with PVD and or vitreoretinal traction 2) Understand the role of scleral buckling in the 2020 armamentarium of the retinal surgeon.

Scleral buckling is the traditional method of retinal detachment repair. In spite of the notable shift towards vitrectomy or vitrectomy with scleral buckle for retinal detachment, buckling alone still has great utility in a variety of retinal detachment settings. We will discuss principles of scleral buckling, the importance of excellent evaluation of the peripheral retina with documentation of findings and development of a preop battle plan and the steps in a buckle especially drainage of subretinal fluid. The place of buckling today in the vitreoretinal surgeon’s arsenal will be deliberated upon. It is best to have many arrows in ones quiver and know which one will fly true in each specific surgical setting.

References: 1) Retinal Detachment, Ron G Michels et al, C V Mosby Co, 1990 2) Controversies in Care: Scleral Depression with Binocular Indirect Ophthalmoscopy, Colciello, Michael, Retinal Physician, May 1, 2019, pp 38-40 3) Retinal Detachment following cataract phacoemulsification- a review of the literature, Qureshi M H and Steel, DHW, Eye (Lond) 2019, Oct 1, doi 1038/s 1433-019-5575-2 epub ahead of print


PNEUMATIC RETINOPEXY: INDICATIONS, TECHNIQUES, AND OUTCOMESAnthony Joseph, MD

OPHTHALMIC CONSULTANTS OF BOSTON, BOSTON, MA

Objectives: 1. To examine the indications, contraindications, advantages, and disadvantages of in-office pneumatic retinopexy for primary retinal detachment repair 2. To review the surgical procedure and instrumentation involved in pneumatic retinopexy.

Introduced in 1986 as an alternative to scleral buckle and pars plana vitrectomy for the repair of primary rhegmatogenous retinal detachment, pneumatic retinopexy remains an important tool for retina specialists. When properly utilized, it can offer lower risk and more rapid visual recovery compared to surgical alternatives. We will review the factors that ophthalmologists must consider when determining if pneumatic retinopexy is appropriate for their patients. We will also discuss the procedure in detail including keys to successful outcomes.

References: 1: Hillier RJ, Felfeli T, Berger AR, Wong DT, Altomare F, Dai D, Giavedoni LR, Kertes PJ, Kohly RP, Muni RH. The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT). Ophthalmology. 2019 Apr;126(4):531-539. doi:10.1016/j.ophtha.2018.11.014. Epub 2018 Nov 22. PubMed PMID: 30468761. 2: Cohen MN, Fine HF, Shah CP. The Role of Pneumatic Retinopexy: Lessons Learned and Keys to Successful Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2017 Aug 1;48(8):611-615. doi: 10.3928/23258160-20170802-02. PubMed PMID: 28810035. 3: Goldman DR, Shah CP, Heier JS. Expanded criteria for pneumatic retinopexy and potential cost savings. Ophthalmology. 2014 Jan;121(1):318-326. doi: 10.1016/j.ophtha.2013.06.037. Epub 2013 Aug 14. PubMed PMID: 23953099. 4: Hilton GF, Grizzard WS. Pneumatic retinopexy. A two-step outpatient operation without conjunctival incision. Ophthalmology. 1986 May;93(5):626-41. PubMed PMID: 3523357. 5: Tornambe PE. Pneumatic retinopexy. Surv Ophthalmol. 1988 Jan-Feb;32(4):270-81. Review. PubMed PMID: 3279561. 6: Tornambe PE, Hilton GF, Kelly NF, Salzano TC, Wells JW, Wendel RT. Expanded indications for pneumatic retinopexy. Ophthalmology. 1988 May;95(5):597-600. PubMed PMID: 3174020.

778th Meeting | 23

MANAGEMENT OF PROLIFERATIVE VITREORETINOPATHY:

WHERE ARE WE TODAY AND WHERE ARE WE GOING?David R. Lally, MD

NEW ENGLAND RETINA CONSULTANTS, SPRINGFIELD, MA

Objective: Understand current management of PVR, Understand future potential therapies for PVR

Outline-PVR definition and incidence-PVR pathophysiology-Anatomical and functional success in recurrent RD repair with PVR

Where are we today in the management of PVR?-Surgical-Timing of intervention-PFO-MembraneBlue, triamcinolone, ICG stains-Perfluoro-n-octane (PFO)-ILM peeling-Retinectomy-Lens removal-Tamponade: Gas versus Silicone Oil

Where are we going in the future with managing PVR?-Adjunctive treatments to prevent cellular proliferation-Intravitreal methotrexate (Aldeyara Therapeutics)-Retinoic acid-Development PVR grading schemes-Genetic, imaging, and biochemical markers

References: Idrees S, Sridhar J, Kuriyan AE. Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin 2019;59(1):221-240. Leiderman YI, Miller JW. Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol. 2009;24(2):62-69. Sadaka A, Risk RA, Other JM, et al. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol Auckl NZ. 2016;10:1811-1817.


MEDIUM-TERM PERFLUORO-N-OCTANE FOR INFERIOR RETINAL DETACHMENTS, GIANT RETINAL TEARS, AND MACULAR PATCH GRAFT

Steve Charles, MD

CHARLES RETINA INSTITUTE, GERMANTOWN, TN

Objectives: 1. Emphasize the benefit of the oxygen carrying capacity of medium term PFO in autologous macular patch graft surgery. 2. Emphasize that medium term PFO for in-ferior, nasal or temporal giant retinal tears eliminates slippage of the tear and facilitates straightforward patient positioning. 3. Emphasize that medium term PFO is ideal for inferi-or detachment without a PVD, a slow PVD occurs during the two weeks PFO is in the eye.

Dr. Charles will discuss the rationales and benefits of employing medium-term PFO (7-14 days) in the following conditions:

1) Inferior retinal detachment without the need for scleral buckle2) Inferior, nasal, or temporal giant retinal tears (GRTs)3) Superior GRT4) Autologous macular patch graft for refractory macular hole.

References: Sigler EJ, Randolph JC, Charles S. Foreign body response within postoperative perfluoro-n-octane for retinal detachment repair. Retina 2014; 34(2):237-246.Sigler EJ, Randolph JC, Calzada JI, Charles S. 25-gauge pars plana vitrectomy with medium-term postoperative perfluoro-n-octane tamponade for inferior retinal detachment. Ophthalmic Surg Lasers Imaging. 2013; 44(1):34-40.Autologous retinal transplant for refractory macular holes: Multicenter International Collaborative Study Group. Ophthalmology 2019;126(10):1399-1408.Krafft MP, Riess JG. Perfluorocarbons: life sciences and biomedical uses. J Polym Sci A Polym Chem. 2007; 45:1185-1198.

778th Meeting | 25

SPECIAL CONSIDERATIONS IN PEDIATRIC RETINAL DETACHMENTCaroline Baumal, MD

NEEC NEW ENGLAND EYE CENTER, BOSTON, MA

Objective: To understand the pathogenesis and risk factors for pediatric retinal detachment. To be aware of pre, intra and post-operative special considerations and develop a plan of action for pediatric retinal detachment repair.

Management of retinal detachment is the pediatric age group requires special considerations. The etiology of the detachment should be considered While adults most often present with rhegmatogenous retinal detachment (RRD), the pathogenesis often differs in children and may include tractional progressive vitreoretinopathies and genetic syndromes. Systemic evaluation, examination under anesthesia and bilateral ocular intervention may be necessary. Delay in diagnosis is common with signs of chronicity affecting the success of surgical repair. Special considerations are needed in every step of the assessment including pre-operatively with family counselling, intraoperatively with surgical adjuvants and equipment requirements and postoperatively with continued retinal examinations and visual rehabilitation.

References: Butler TKH, Kiel AW, Orr GM. Anatomic and visual outcomes of retinal detachment surgery in children. Br J Ophthalmol 2001;85:1437-1439. Lam WC, Gan NY. Retinal detachments in the pediatric population. 2018;8:222-236. Read S, Aziz HA, Kuriyan A et al. Retinal detachment surgery in a pediatric population: visual and anatomic outcomes. Retina 2018;28:1393-1402.


FAILURE MODES IN RETINAL DETACHMENT SURGERYSteve Charles, MD

CHARLES RETINA INSTITUTE, GERMANTOWN, TN

Objectives: 1. Emphasize the utility of Schlieren optical effect, collagen fiber bundle orien-tation and pigmentation to find retinal breaks during vitrectomy for retinal detachment. 2. Emphasize listening for details of patient shadow progression history in locating initialretinal breaks and detachment. 3. Emphasized the role of vitrectomy under air in locating residual vitreous traction and removing it using interface vitrectomy.

As will be discussed in this lecture, there are many causes of failed retinal detachment surgery; we will discuss techniques to improve outcomes and reduce complications. The most common causes of failed retinal detachment surgery include:

1) Poor visualization (cataract, IOL fogging)2) Failure to identify all retinal breaks and residual vitreoretinal traction3) Multiple rows of 360 degree interrupted, rather than confluent, laser retinopexy4) Excessive retinopexy5) Lensectomy without complete removal of the capsule

References: Sodhi A, Leung LS, Do DV, Gower EW, Schein OD, Handa JT. Recent trends in the management of rhegmatogenous retinal detachment. Survey of Ophthalmology, 2008;5:50–67.Williamson TH, Lee EJ, Shunmugam M. Characteristics of rhegmatogenous retinal detachment and their relationship to success rates of surgery. Retina (Philadelphia, Pa). 2014;34(7):1421-7.Kuhn F, Aylward B. Rhegmatogenous retinal detachment: a reappraisal of its pathophysiology and treatment. Ophthalmic research. 2014;51(1):15-31.Sigler EJ, Randolph JC, Calzada JI, et al. Pars Plana Vitrectomy With Medium-Term Postoperative Perfluoro-N Octane For Recurrent Inferior Retinal Detachment Complicated By Advanced Proliferative Vitreoretinopathy, Retina. 2013;33:1–7.Machemer R. Cutting of the retina: a means of therapy for retinal reattachment (author’s transl) Klin Monbl Augenheilkd. 1979;175(5):597–601

778th Meeting | 27

ADVENTURES IN TRACTIONAL RETINAL DETACHMENT REPAIRKristen Nwanyanwu, MD, MBA

YALE SCHOOL OF MEDICINE, NEW HAVEN, CT

Objectives: 1. Pathophysiology of the development of diabetic tractional retinal detachment 2. Surgical management considerations in diabetic tractional retinal detachment.

Dr. Nwanyanwu will illustrate the management of tractional retinal detachment in a case-based presentation. She will present the pathophysiology of how tractional retinal detachment develops, indications for repair, preoperative management, surgical techniques, and outcomes.

References: Brunner, Simon and Binder, Susanne. “Surgery for Proliferative Diabetic Retinopathy” Ryan’s Retina. Ed. Andrew P. Schachat. 6th ed. Vol. 3. Elsevier. 2018. Online. Meleth A, Carvounis P. Outcomes of Vitrectomy for Tractional Retinal Detachment in Diabetic Retinopathy. International Ophthalmology Clinics (2014). 54(2):127-139. Charles S, Flinn CE. The natural history of diabetic extramacular traction retinal detachment. Arch Ophthalmol. 1981;99:66–68. The DRVS Study Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) Report #1. Ophthalmology. 1985;92:492–502. Zhao L, Zhu H, Zhao P, et al A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy British Journal of Ophthalmology 2011;95:1216-1222. Oshima et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmol 2009;116:927-38. da R Lucena D et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688-91. Pokroy et al. Bevacizumab prior to vitrectomy for diabetic tractional retinal detachment. Eye 2011;25:989-997. Meleth A, Carvounis P. Outcomes of Vitrectomy for Tractional Retinal Detachment in Diabetic Retinopathy. International Ophthalmology Clinics (2014). 54(2):127-139.


FINANCIAL DISCLOSURE INFORMATION

As a provider accredited by the Massachusetts Medical Society, NEOS must ensure balance, independence, objectivity, and scientific rigor in all its individually and jointly provided educational activities. All individuals in a position/role to control the content of an activity are expected to disclose to NEOS any relevant financial relationships they and their spouse/partner have with commercial interests.

The ACCME defines a commercial interest as any entity producing, marketing, reselling or distributing health care goods or services consumed by, or used on, patients. Relevant financial relationships are financial relationships in any amount, which occurred in the twelve-month period preceding the time that the individual was asked to assume a role controlling content of the CME activity, and which relate to the content of the educational activity.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as independent contractor (including contracted research), consulting, promotional speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The MMS/ACCME considers relationships of the person involved in the CME activity to also include financial relationships of a spouse or partner.

Ansari, Husam:Consulting Fees - Name of Relevant Commercial Entity(ies): Allergan, New World Medical, IvantisContracted Research - Name of Relevant Commercial Entity(ies):Allergan, Ivantis

Arroyo, Jorge:Ownership Interest: Envision Diagnostics

Bradbury, Michael:Ownership Interest: Regeneron, Chase and Associates, Inc (Iviews imaging system)

Baumal, Caroline:Fees for Non-CME Services Received Directly from Commercial Interest or their Agents:Genentech: Speaker Bureau; Zeiss: Speaker Bureau

Ciolino, Joseph:Receipt of Intellectual Property Rights / Patent Holder - Name of Relevant Commercial Entity(ies):Co-author for a patent for drug-eluting contact lens

778th Meeting | 29

Consulting Fees - Name of Relevant Commercial Entity(ies):Paid Consultant for TheroptixOwnership Interest - Name of Relevant Commercial Entity(ies):Co-founder with equity in Theroptix

Dagianis, John:Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Lumenis, Speaker Bureau

Fogel, Erin S.:Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Paid Speaker for Allergan

Heier, Jeffrey:Consulting Fees - Name of Relevant Commercial Entity(ies):4D Molecular Technologies, Adverum, Aerie, Aerpio, Akros, Aldeyra, Alkahest, Allegro, Apellis,Array, Asclepix, Bayer, BVI, BioMarin, Daiichi-Sankyo, Eloxx, Galecto, Galimedix, Genentech/Roche, Generation Bio, Helio, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong,Kodiak, Notal Vision, Novartis, Ocular Therapeutix, Omeicos, Orbit Biomedical, Oxurion, Regeneron, Regenxbio, Retrotope, Scifluor, Shire, Stealth Biotherapeutics, Voyant, ZeissContracted Research - Name of Relevant Commercial Entity(ies):Aerpio, Apellis, Clearside, Daiichi Sankyo, Genentech/Roche, Genzyme, Hemera, Janssen R&D, Kalvista, Kanghong, Novartis, Ocudyne, Ophthotech, Optos, Optovue, Oxurion, Regeneron, Regenxbio, ScifluorOwnership Interest - Name of Relevant Commercial Entity(ies):Adverum, Aldeyra, Allegro, Digital Surgery Systems, jCyte, Ocular Therapeutix

Lally, David R.:Contracted Research: Aldeyara Therapeutics

Nguyen, Quan Dong:Consulting Fees - Name of Relevant Commercial Entity(ies):Bayer, EyePoint, Genentech, Gilead, Mallinckrodt, Regeneron, SantenContracted Research - Name of Relevant Commercial Entity(ies):Genentech, Gilead, Mallinckrodt, Regeneron, SantenUnlabeled/Unapproved Uses of Drugs or Products:Sirolimus, Tocilizumab

Rizzo, Joseph:Receipt of Intellectual Property Rights/Patent Holder: Bionic Eye TechnologiesConsulting Fees: GenSightOwnership Interest: Bionic Eye Technologies

NO FINANCIAL INTERESTNone of the other individuals in a position to control the content of this activity, including planners, CME Review Committee members, faculty presenters, moderators, panelists and reviewers have any relevant financial relationship with an ACCME-defined commercial interest to disclose.


HOTEL COMMONWEALTH500 Commonwealth Avenue, Boston, MA

DATE TOPIC MODERATOR

October 30, 2020Retina-Diabetes Nauman Chaudhry, MD

Plastics – Trauma Daniel Lefebvre, MD

December 4, 2020Infectious Uveitis Pryja Janardhana, MD

Cataract Lauren Shatz, MDTWO DAY MEETING

(Friday/Saturday)

March 12, 2021

Glaucoma Manishi Desai, MD

Neuro-ophthalmology Emergencies Marc Bouffard, MD

March 13, 2021Ethics and Risk Management Mary Daly, MDPractice Management John Mandeville, MD

May 14, 2021Excimer Based Refractive Surgery Jason Brenner, MD

Corneal Surgery Peggy Chang, MD

FUTURE NEOS MEETINGS

JUNE 5, 2020 OCULAR TRAUMA MAGDALENA KRZYSTOLIK, MD

SUBDAY: NEURO-OPHTHALMOLOGY CRANDALL PEELER, MD

UVEITIS NINANI KOMBO, MD

STRABISMUS OREN WEISBERG, MD

DATE TOPIC MODERATOR

June 5 Ocular Trauma Magdalena Krzystolik, MD Subday: Neuro-ophthalmology

Uveitis Strabismus

Crandall Peeler, MD Ninani Kombo, MD Oren Weisberg, MD

778th Meeting | 31

THE BOARD AND COMMITTEES 2019-2020

The Board Mary Daly, MD, PresidentJorge Arroyo, MD, President-electJay Duker, MD, Vice-President, Chair Admissions CommitteeDonna Siracuse-Lee, MD, SecretaryLaura Fine, MD, Immediate Past President, Chair Nominations CommitteeJohn Dagianis, MD, Past President, Chair Policies CommitteeJeffrey Heier, MD, Past PresidentJoseph Rizzo, MD, Treasurer, Chair Finance CommitteeJoel Geffin, MD, Chair Program CommitteeMichael Price, MD, Chair Educational Endowment Fund CommitteePhil Aitken MD, Chair Ophthalmic Services CommitteeBrendan McCarthy, MD, Chair Public Health and Education CommitteeAngela Turalba, MD, Director of Continuing EducationAnita Shukla, MD, Chair Young Ophthalmologists CommitteeMichelle Liang, MD, Chair, I.T. CommitteeMichael Bradbury, MD, Executive Director

COMMITTEES:

Executive CommitteeMary Daly, PresidentJorge Arroyo, MD, President-electJoseph Rizzo MD, TreasurerMichael Bradbury, MD, Executive Director (ex officio)

Admissions CommitteeJay Duker, MD, ChairMary Daly, MD

Finance CommitteeJoseph Rizzo, MD, ChairMary Daly, MD Jorge Arroyo, MD (ex officio)Michael Bradbury, MD (ex officio)

Nominations CommitteeLaura Fine, MD, ChairAnn Bajart, MD (MA)Mitchell Gilbert, MD (CT)Elliot Perlman, MD (RI)Christopher Soares, MD (VT)David Weinberg, MD (NH)

ex officio members:Drs. Bradbury, Siracuse-Lee, Fine, Heier, Levy)

Program CommitteeJoel Geffin, MD, ChairFina Barouch, MDEdward Feinberg, MDGena Heidary, MDJeremy Kieval, MDJohn Papale, MDShlomit Schaal, MDLucia Sobrin, MDAngela Turalba, MDMichael Yoon, MDLaura Fine, MD (ex officio)Mary Daly, MD (ex officio)Michael Bradbury, MD (ex officio)

JUNE 5, 2020 OCULAR TRAUMA MAGDALENA KRZYSTOLIK, MD

SUBDAY: NEURO-OPHTHALMOLOGY CRANDALL PEELER, MD

UVEITIS NINANI KOMBO, MD

STRABISMUS OREN WEISBERG, MD


Public Health and Education Committee

Brendan McCarthy, MD, ChairSherleen Chen, MDRobert Daly, MDMacie Finkelstein, MDMagdalena Krzystolik, MDVasiliki Poulaki, MDChristopher Soares, MDCathryn Welch, MDMary Daly, MD (ex officio)John Dagianis, MD (ex officio)

Society Policies Committee

John Dagianis, MD, ChairMichael Bradbury, MD

Ophthalmic Services Committee

Phil Aitken, MD, ChairHusam Ansari, MDTimothy Blake, MDJohn Dagianis, MDNicoletta Fynn-Thompson, MDKathryn Hatch, MDMarc Leibole, MDDavid Vazan, MDRobert Westcot, MDPeter Zacharia, MDJorge Arroyo, MD (ex officio)Laura Fine, MD (ex officio)

Committee for Educational Endowment Fund

Michael Price, MD, ChairThomas Coghlin, MDJohn Dagianis, MDFrancis D’Ambrosio, MDRichard Dornfeld, MDMatthew Gardiner, MDGrace Lee, MDDavid Lawlor, MDJoseph Rizzo, MD

Information Technology Committee

Michelle Liang, MD, ChairDavid Ramsey, MDNaveen Rao, MDAnkoor Shah, MDJohanna Seddon, MD

Jorge Arroyo, MDElliot Perlman, MD, (emeritus)Mary Daly, MD (ex officio)

Young Ophthalmologists Committee

Anita Shukla, MD, ChairJoanne Chang, MDJeffrey Heier, MDStephen Anesi, MDNicole Siegal, MDJennifer Cartwright Garvey, MDElizabeth Houle, MDHyunjoo Lee, MDMichelle Liang, MDDan Lefebvre, MDJoshua Ney, MDArchana Seethala, MDJorge Arroyo MD (ex officio)Michael Bradbury (ex officio)Michael Price, MD (ex officio)

Miguel G. Ocque, Administrative Director

778th Meeting | 33

TODAY’S EXHIBITORS (at time of printing)

SPONSOR LEVEL

Alcon - SPONSOR817.293.0450

www.alconlabs.com

Shire - SPONSOR781.869.7620www.shire.com

EXHIBITOR LEVEL

Aerie Pharmaceuticals203.901.8851

www.aeripharma.com

Allergan774.991.1187

www.allergan.com

Bio-Tissue508.808.3017

www.biotissue.com

Dompé833.366.7387www.dompe.com

Eyepoint Pharmaceuticals833.393.7646

www.eyepointpharma.com

Genentech800.551.2231www.gene.com

J&J Surgical Vision

Microsurgical Technology

Ocular Therapeutix877.628.8998

www.dextenza.com

Ophthalmic Instrument Company800.272.2070

www.oic2020.com

Optovue Inc.510.623.8868www.optovue.com

Regeneron510.623.8868

hcp.eylea.us

ScienceBased Health281.885.7727

www.sbh.com

Sun Ophthalmics609.720.5629

www.sunophthalmics.com

Zeiss Meditec, Inc925.856.2574

www.zeiss.com/med


NEW ENGLAND OPHTHALMOLOGICAL SOCIETY EDUCATIONAL ENDOWMENT FUND DONORS

Diamond Patrons $100,000 or more

Dr. Michael J. BradburyIn memory of Dr. C. Davis BelcherIn memory of Dr. Hal M. Freeman

Dr. C. Stephen FosterMassachusetts Eye and Ear Infirmary

In honor of Dr. Joan MillerDr. and Mrs. Paul M. Pender

In Memory of Paul D. Pender and Harry V. Carey

Dr. and Mrs. Richard J. SimmonsIn memory of Dr. Ruthanne Simmons

Ophthalmic Consultants of BostonPhysicians and Patients

In honor of Dr. B. Thomas Hutchinson

Platinum Patrons $10,000 to $99,999

Boston Eye ResearchIn memory of Dr. Sanford Hecht

Dr. John DagianisIn memory of Dr. Hal M. Freeman, In honor of James and Eleanor Dagianis, and Paul and Verna Dobbins

Dr. and Mrs. Stuart DuBoffIn memory of Dr. Ruthanne SimmonsIn honor of Samuel and Gloria DuBoff and William and Diane Brown

Dr. Hal M. FreemanDr. Albert R. Frederick, Jr.

In honor of B. Thomas HutchinsonDr. and Mrs. Joseph J. GrecoThe Health Foundation of Central Massachusetts

In honor of Dr. Michael J. BradburyHOYA Optical LaboratoriesDr. B. Thomas HutchinsonNew Hampshire Society of Eye Physicians and Surgeons

Dr. Delia Sang and Dr. Mark HughesIn memory of Dr. Charles L. Schepens

Dr. Gerald SpindelIn honor of Israel and Rose Spindel and

Benjamin Burch

Gold Patrons $3,000-$9,999

Dr. Jorge ArroyoDr. William AtleeDr. Ann Bajart

In honor of Judy Cerone KeenanDrs. A. Robert and Jean Bellows

In memory of Dr. W. Morton GrantDr. Thomas Coghlin

In honor of Dr. Mary Daly, Dr. Ira Asher,Dr. Kevin O’Brien, and Dr. Reid Appleby, Jr.

Dr. and Mrs. Paul P. DunnIn memory of Dr. C. Davis Belcher and in honor of Dr. A. Robert Bellows

Dr. Joel GeffinDr. C. Mitchell Gilbert

In honor of Drs. Claes Dohlman, Kenneth Kenyon, and Martin Wand

Dr. and Mrs. Donald KaplanIn memory of Dr. Robert Vernlund

Jean Keamy for the Keamy Family Foundation

In memory of Donald and Yvonne KeamyMaine Society of Eye Physicians and SurgeonsNew England Lens Implant Society

In memory of Dr. Sanford HechtDr. and Mrs. Elliot Perlman

In memory of Drs. C. Davis Belcher and Kathleen Maguire

Dr. Michael RaizmanDr. Shiyoung Roh and Mrs. Myung Ja RohDrs. Helen and Jack Schinazi

778th Meeting | 35

In memory of Dr. C. Davis BelcherDr. and Mrs. John Sebestyen

In memory of Dr. Taylor R SmithDr. Bradford J. Shingleton

In honor of Drs. Albert R. Frederick,B. Thomas Hutchinson, Silvio Von Pirquet and A. Robert Bellows

Drs. Richard and Ruthanne SimmonsIn memory of Dr. W. Morton Grant

Dr. and Mrs. Richard J. SimmonsIn memory of Drs. Paul A. Chandler, W. Morton Grant, Ruthanne Simmons, and C. Davis Belcher

Dr. and Mrs. Paul WassonIn memory of Dr. Paul WassonIn memory of Dr. Oscar Hollander

Dr. and Mrs. Hal WoodcomeIn memory of Dr. Harold Woodcome, Sr.

Estate of Dr. Leon Zimmerman

Silver Patrons $1,000-$2,999

Dr. Reid S. Appleby, Jr.In honor of Dr. Harold Woodcome, Jr., and Associates in Honor of Dr. Robert Bahr

Dr. and Mrs. Lloyd M. AielloDr. Robert BahrDr. C. Davis Belcher

In honor of Dr. Richard SimmonsDr. Harry Braconier

In memory of Drs Taylor Smith, Karl Riemer, Carl C. Johnson.

In memory of Dr. Hal M. FreemanDr. and Mrs. Sheldon M. BuzneyChildren’s Hospital Ophthalmology FoundationDr. and Mrs. William E. Clark, Jr.Dr. Mary Daly

In memory of Dr. and Mrs. William J. DalyDr. Joseph L. Dowling, Jr.Dr. Jay S. DukerEye Health Services

In memory of Dr. C. Davis BelcherDr. Laura FineDr. and Mrs. David GreenseidDr. Bernard Heersink

Dr. Jeffrey Heier Dr. Ralph HinckleyDr. William S. Holt Dr. Robert T. LacyDr. Joseph Levy

In honor of Dr. Thomas Hedges IIIDr. Byron S. LingemanDr. Richard LowDr. Kathleen Maguire and Stephen Burke

In memory of Dr. Hal M. FreemanDr. Lisa McHamDr. Clifford Michaelson

In memory of Dr. Jesse and Mrs. Ruth Lee MichaelsonDr. Stanislaw Milewski

In memory of Dr. Taylor R. Smith Dr. Peter B. Mooney

In memory of Dr. Henry F. AllenDr. Paul MoultonDr. Dale OatesDr. Stephen J. PhippsDr. and Mrs. Michael PriceDrs. Shiyoung Roh and John WeiterDr. and Mrs. George Santos Dr. Delia Sang

In honor of Dr. Lloyd M. AeilloDrs. Jack and Helen Schinazi

In memory of Mrs. Mary SantosIn honor of Dr. Irving L. Pavlo

Dr. Roger F. SteinertIn honor of Drs. A. Robert Bellows, S. Arthur Boruchoff, Albert R. Frederick, and B. Thomas Hutchinson

Dr. J. Elliott TaylorDr. Felipe I. Tolentino

In honor of Drs. Hal M. Freeman and Roland Houle

In memory of Dr. Charles L. SchepensDr. Trexler R. ToppingVermont Ophthalmological SocietyDr. Martin Wand

In memory of Dr. W. Morton GrantDrs. Peter Wassermann, T. Gordon Hand, Christie Morse and Bradford Hall,

In memory of Dr. John DetwillerIn honor of Dr. Lewis Stieglitz

Master William Weiter


In honor of Ann Bajart and Tony Schemmer, and Deborah and Elliot Perlman

Dr. Kenneth WolfDr. Allen Zieker

Benefactors $500-$999

Dr. Phil AitkenIn memory of Drs. Robert Guiduli and Simmons Lessell

Maria CaponeIn Memory of Dr. Y. Jacob Schinazi

Dr. Michael CooperIn honor of Dr. Brendan McCarthyIn memory of Dr. Robert HaimoviciDr. Behrooz Koleini and Dr. S. Arthur

BoruchoffDrs. Elliot and Macie FinkelsteinDr. David Fleishman

In memory of Dr. Gary B. Fleishman Dr. George GarciaDr. Timothy Goslee

In honor of Dr. Mary DalyDr. Robert Guiduli

In memory of Dr. Kathleen J. MaguireDr. Lynne KaplinskyDr. Robert LytleMaine Eye CenterDr. Brendan McCarthy

In Memory of Dr. Behrooz KoleiniDr. and Mrs. Howard MartonDr. Christopher NewtonOphthalmic Consultants of BostonRetina Center of MaineRhode Island Society of Physicians and Surgeons Dr. Joel SchumanDr. Lewis StieglitzDr. Dennis StolerDr. Barry WepmanDr. Charles Wingate

Sponsors $250-$499

Dr. Caroline BaumalIn memory of Dr. Jose Berrocal

Dr. Francis Y. Falck, Jr.Dr. Ralph A. Goodwin, Jr.Dr. Dana GraichenDr. Payson B. Jacobson

In memory of Dr. Abraham Pollen Dr. Glenn P. KimballDr. Peter LouDr. Carmen PuliafitoDr. Sarkis Soukiasian

In Honor of Dr. Roger SteinertDr. Caldwell W. SmithDr. Neal G. SneboldDr. Jonathan TalamoDr. Yvonne Tsai

In memory of Helena ToksozDr. Andrew Wong

In memory Dr. Charles L. Schepens Worcester Ophthalmology Associates Dr. Charles Zacks

Friends Up to $250

In Memory of Dr. Y. Jacob SchinaziNancy Asbedian Lois FainMarion J. GoldsmithRobert & Lorraine KingsburyDiane KlaiberWilliam & Ingrid MercerMichael MiglioriDr. & Mrs. Samir MoubayedBeth OrsonDr. Virginia Schmidt ParkerKarl StephensJanice Solomon

In Memory of C. Davis Belcher Accent EyewearJames BernsonDr. Charles Beyer-MachulePhilip Cacciatore Eye Health ServicesMilton Feinson Dr. Richard GetnickEvelyn JohnDr. Ernest KornmehlDon Lesieur

778th Meeting | 37

Joyce MarshallRebecca MurphyTherese O’KeefeDr. Stephen Poor, IIIEileen Raffferty Elizabeth Reece Dr. Richard SimmonsMarian Spilner Dr. Ann StrombergElizabeth SullivanAndrienne TashjianThe Rivers School

In Memory of Dr. Peter Gudas:Naomi LitrowinikMercedes SaylerNeedham Psychotherapy AssociatesNew England Carpenters Health FundNorfolk Lodge A.F. and A.M. James and Jean TwyningJacqueline PepperJeanne Smith

Dr. Peter BatsonDr. Richard BrownDr. David CorbitDr. Paul Cotran

In memory of Dr. Mariana Mead Dr. Peter DonshikDr. Stuart Fay

In honor of Dr. Michael Bradbury and Dr. Tuck

Melvyn and Eleanor Galin FoundationIn honor of B. Thomas Hutchinson

Dr. Andrew GilliesIn memory of Dr. Moshe Lahav

Dr. Timber GormanDr. Jay Gooze

In memory of Kirstyn SmithDr. Amy GregoryDr. Walter GriggsDr. Robert HermDr. Ted HouleDr. Glenn P. KimballDr. David LawlorDr. Howard M. Leibowitz

In memory of Dr. Behrooz KoleiniDr. Clifford Michaelson

In memory of Dr. Behrooz KoleiniDr. Lawrence PiazzaDr. Theodore RennaMolly-Jane Isaacson Rubinger

In honor of Trexler ToppingDr. Donna Siracuse-LeeAlice Sarno

In memory of B. Thomas HutchinsonDr. Domenic M. StrazzullaDr. Carter TallmanDr. Michael Wiedman

In honor of Dr. Claes Dohlman

NEOS SCIENTIFIC POSTER PROGRAMHecht Awards for Best Resident, Fellow, and Trainee Posters

June 5, 2020Residents, fellows, and trainees from all the New England ophthalmologic teaching programs are invited and encouraged to submit abstracts for a scientific poster presentation contest to be conducted at the June 5, 2020, NEOS meeting. Posters will be judged on originality and scientific merit. Awards will be made for the first prize $500.00, second prize $300.00, third prize $200.00 and three honorable mentions of $50.00 each. Funding for the awards is derived from a gift to the NEOS Education Endowment Fund honoring the late Sanford Hecht, MD. Poster presentations exhibited at ARVO in 2020 and at the AAO meeting in 2019 may be submitted. We encourage all trainees to participate in this event. Medical Student work is welcome for presentation.

To submit posters, go to neos-eyes.org – future meetings/June5/abstract submission form. Deadline for abstract to appear in printed program May 8. Others may be accepted as space allows.

Poster format information will be available within the next few weeks.

For questions, please contact NEOS at 781/434-7656 or [email protected]

www.neos-eyes.org

Follow us @NEOS_Eyes

Documents

meeting of the New England Ophthalmological Society...Staff have been furloughed. Practices are under severe financial strain and stress. And yet, there are so many good things too